**Cipla Remains Unfazed by Potential US Tariffs on Pharmaceuticals**
Cipla’s managing director and global CEO, Umang Vohra, has stated that the company does not anticipate any immediate effects from potential tariffs on pharmaceutical imports that may be imposed by the US or from President Trump’s recent directive aimed at reducing prescription drug prices. Vohra emphasized that business operations continue as normal, with no disruptions in the US due to tariff-related uncertainties. “We don’t see the impact,” he remarked, adding that the company is closely monitoring ongoing trade discussions between the US and Indian governments. He expressed confidence that the generics market would not experience significant changes.
While President Trump has yet to announce specific tariffs on pharmaceutical products, he has suggested that separate tariffs could be introduced to encourage domestic manufacturing. Regarding the executive order signed by Trump, which aims to lower prescription drug prices by 59% in the US, Vohra noted that further clarification is needed. He believes the order will primarily affect branded innovator drugs, stating, “Generic prices in the US are already very significantly comparable with the rest of the world, and in some cases, lower.”
Cipla recently reported its Q4FY25 results, revealing a 9% year-on-year revenue increase to ₹6,730 crore, with a profit after tax of ₹1,222 crore, marking a 30% rise from the previous year. The company also reported an EBITDA of ₹1,538 crore, reflecting a margin of 22.8%. For the full fiscal year FY25, Cipla’s revenue reached ₹27,548 crore, an 8% increase year-on-year, with a profit after tax of ₹5,273 crore, up 28% year-on-year.
Cipla’s One India Business demonstrated robust growth, increasing by 8% year-on-year during the quarter, with its branded prescription segment outpacing market growth in key chronic therapies. The North America division reported quarterly revenue of $221 million, achieving an all-time high annual revenue of $934 million, driven by strong performance in differentiated assets, which accounted for 29% of the company’s total revenues.
Looking ahead, Vohra expressed optimism about maintaining growth momentum, highlighting a pipeline of upcoming launches that are expected to drive expansion in the US market. He acknowledged that while the company will face reduced exclusivity on the blockbuster drug Lenalidomide (Revlimid) over the next two years, Cipla is well-positioned for a new trajectory of growth.
**FAQ**
*What impact do potential US tariffs have on Cipla?*
Cipla does not expect any immediate impact from potential US tariffs on pharmaceuticals, as business operations remain unaffected and the company is closely monitoring trade developments.
